Roche's closely watched immunotherapy fails key study in tough-to-treat lung cancer

[cafead]

via A drug combination including the Roche immunotherapy tiragolumab failed a Phase 3 trial in a tough-to-treat form of lung cancer, a setback for a closely watched group of medicines that work by targeting a protein called TIGIT.

article source